Contents
Clinical research in Maine coordinates and supports advancements in the field of medicine. The state’s leading experts are focused on improving diagnostic medicine, personalized care, quality of life, and survival rates.
Health volunteers, such as yourself, serve as a bridge between medical research and development. With your help, experts can develop new methods that can save people of all ages. We are here to help you find clinical trials that can suit your needs.
Clinical Trials For Disease Areas in Maine
Clinical research trials in Maine tackle the most difficult health problems in the U.S., one breakthrough at a time. Some of the most critical areas studied are cancer research, cardiology, neurological disorders, infectious diseases, and psychiatric health.
For example, Maine Medical Center joined two global human clinical trials for a medication that could treat COVID-19. The trials for remdesivir may provide notable results for both severe and moderate coronavirus cases.
Every participant makes a difference. Apply for a clinical trial today and become a part of the latest research. Check out the trial feed below to find out more.
Fabry Disease Registry & Pregnancy Sub-registry
Recruiting
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
* To enhance the understanding of the variability, progression, and natural history of F... Read More
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
* To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease;
* To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care;
* To characterize and describe the Fabry population as a whole;
* To evaluate the long-term safety and effectiveness of Fabrazyme®
Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development/reimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/07/2025
Locations: Maine Medical Center Pediatrics- Site Number : 840064, Portland, Maine
Maine Medical Center Pediatrics- Site Number : 840064, Portland, Maine
Conditions: Fabry Disease
Pompe Disease Registry Protocol
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.
The objectives of the Registry are:
* To enhance understanding of t... Read More
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
* To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
* To characterize the Pompe disease population.
* To evaluate the long-term effectiveness of alglucosidase alfa. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/06/2025
Locations: Maine Medical Center Pediatrics- Site Number : 840064, Portland, Maine
Maine Medical Center Pediatrics- Site Number : 840064, Portland, Maine
Conditions: Glycogen Storage Disease Type II, Pompe Disease
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
Recruiting
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural... Read More
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
* To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
* To characterize the Gaucher disease population.
* To evaluate the long-term effectiveness of imiglucerase and of eliglustat.
Gaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/12/2025
Locations: Maine Medical Center Pediatrics- Site Number : 840064, Portland, Maine
Maine Medical Center Pediatrics- Site Number : 840064, Portland, Maine
Conditions: Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Recruiting
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. Read Less
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/14/2025
Locations: Eastern Maine Medical Center, Bangor, Maine +1 locations
Eastern Maine Medical Center, Bangor, Maine
Maine Children's Cancer Program, Scarborough, Maine
Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Recruiting
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
05/22/2025
Locations: Maine Children's Cancer Program, Scarborough, Maine
Maine Children's Cancer Program, Scarborough, Maine
Conditions: Hodgkin Lymphoma in Remission, Leukemia in Remission, Lymphoblastic Lymphoma, Osteosarcoma, Recurrent Leukemia, Recurrent Lymphoma, Recurrent Malignant Neoplasm
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Harold Alfond Center for Cancer Care, Augusta, Maine +13 locations
Harold Alfond Center for Cancer Care, Augusta, Maine
Eastern Maine Medical Center, Bangor, Maine
Waldo County General Hospital, Belfast, Maine
MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford, Biddeford, Maine
Lafayette Family Cancer Center-EMMC, Brewer, Maine
Maine Center for Cancer Medicine-Kennebunk, Kennebunk, Maine
Stephens Memorial Hospital, Norway, Maine
Mercy Hospital, Portland, Maine
Penobscot Bay Medical Center, Rockport, Maine
MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford, Sanford, Maine
Maine Center for Cancer Medicine-Scarborough, Scarborough, Maine
Maine Medical Center- Scarborough Campus, Scarborough, Maine
Maine Medical Partners - South Portland, South Portland, Maine
Maine Center for Cancer Medicine-Topsham, Topsham, Maine
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
Recruiting
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the c... Read More
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2025
Locations: Harold Alfond Center for Cancer Care, Augusta, Maine +4 locations
Harold Alfond Center for Cancer Care, Augusta, Maine
Eastern Maine Medical Center, Bangor, Maine
Lafayette Family Cancer Center-EMMC, Brewer, Maine
New England Cancer Specialists - Kennebunk, Kennebunk, Maine
New England Cancer Specialists, Westbrook, Maine
Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Project: Every Child for Younger Patients With Cancer
Recruiting
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care. Read Less
Gender:
ALL
Ages:
25 years and below
Trial Updated:
08/08/2025
Locations: Eastern Maine Medical Center, Bangor, Maine +1 locations
Eastern Maine Medical Center, Bangor, Maine
Maine Children's Cancer Program, Scarborough, Maine
Conditions: Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Lymphoproliferative Disorder, Myeloproliferative Neoplasm, Stromal Neoplasm, Carcinoma In Situ, Malignant Solid Neoplasm, Desmoid Fibromatosis, Ganglioneuroma, Melanocytic Neoplasm, Neuroendocrine Neoplasm, Adrenal Gland Pheochromocytoma, Malignant Neoplasm, Neoplasm of Uncertain Malignant Potential, Childhood Kidney Neoplasm
Immunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS)
Recruiting
This is a prospective, observational study to investigate molecular mechanisms mediating the systemic inflammatory process, and changes to metabolism, and their impact on brain injury, survival, and functional outcomes after cardiac arrest. Investigators have shown that cardiac arrest induces changes in the numbers and properties of circulating immune cells, shifting the balance towards a pro-inflammatory phenotype and there is increased interest in the inflammatory pathways and the signaling me... Read More
This is a prospective, observational study to investigate molecular mechanisms mediating the systemic inflammatory process, and changes to metabolism, and their impact on brain injury, survival, and functional outcomes after cardiac arrest. Investigators have shown that cardiac arrest induces changes in the numbers and properties of circulating immune cells, shifting the balance towards a pro-inflammatory phenotype and there is increased interest in the inflammatory pathways and the signaling mechanisms through which they are modulated. Participants will undergo blood sampling during 7 days following cardiac arrest, and analyses performed. Patient characteristics, clinical circumstances, and outcomes will be recorded and their associations with these inflammatory pathways characterized. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Maine Medical Center, Portland, Maine
Maine Medical Center, Portland, Maine
Conditions: Cardiac Arrest, Inflammation, Obesity, Hypoxic Ischemic Encephalopathy (HIE)
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Recruiting
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
\*\*\*\*\*\*\*\*\*\*\*\*\*... Read More
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Read Less
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/15/2025
Locations: Harold Alfond Center for Cancer Care, Augusta, Maine +18 locations
Harold Alfond Center for Cancer Care, Augusta, Maine
Jackson Laboratory - Maine Cancer Genomics Initiative, Augusta, Maine
Waldo County General Hospital, Belfast, Maine
SMHC Cancer Care and Blood Disorders -Biddeford, Biddeford, Maine
Northern Light Cancer Care, Brewer, Maine
Raish Peavey Haskell Children's Cancer and Treatment Center, Brewer, Maine
MaineHealth Cancer Care -Brunswick, Brunswick, Maine
New England Cancer Specialist, Kennebunk, Maine
York Hopsital Oncology & Infusion Care in Kittery, Kittery, Maine
Stephens Memorial Hospital, Norway, Maine
Penobscot Bay Medical Center, Rockport, Maine
SMHC Cancer Care and Blood Disorders -Sandford, Sanford, Maine
Maine Children's Cancer Program, Scarborough, Maine
Maine Medical Partner's Women's Health, Scarborough, Maine
New England Cancer Specialist, Scarborough, Maine
MaineHealth Cancer Care -South Portland, South Portland, Maine
New England Cancer Specialist, Topsham, Maine
York Hospital Oncology & Infusion Care in Wells, Wells, Maine
York Hospital Oncology & Infusion Care in York, York, Maine
Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Paid Clinical Trials in Maine
People who participate in paid clinical trials receive compensation for their efforts. The amount ranges based on the study’s duration and requirements. Every study will provide you with compensation details.
Paid clinical trials come with other benefits as well. All necessary study-related healthcare and medications are provided free of charge. By participating, you help doctors evaluate the potency of a new drug, compare it to other medications, and gain valuable insight.
Clinical Trials For Health Volunteers in Maine
Research teams in Maine are looking for specific volunteers based on the condition and drug they study. Phase 1 studies usually require healthy volunteers. However, some may involve patients with a certain health condition, like cancer, liver disease, or HIV. Check the requirements of the study you are interested in before you apply.
Here is a list of the currently available and upcoming clinical research trials near you.
No trials could be found at this time
Medical Discoveries and Innovation in Maine
Maine research institutions have made remarkable contributions to medical science. Their ingenuity and dedication drive progress and benefit patients from all around the world. Some of their achievements deserve special notice. Like:
- Lyme Disease Research: Maine has a tracking program that shows the water quality in a well. The program displays town-level measures, which come from data collected from over 11,000 water tests. This tracking data can boost prevention and promote early detection of Lyme disease.
- Limb Regeneration Research: Scientists at the Mount Desert Island Biological Laboratory in Bar Harbor, Maine, have made remarkable progress in studying limb regeneration in certain amphibians. Their research can be highly beneficial for regenerative medicine in humans.
- Diabetes Research: The Jackson Laboratory has been instrumental in studying diabetes through genetic research. Their clinical trials provide insight into the genetic factors that influence the disease.
Why Maine Is A Great Place For Clinical Research
Maine clinical research relies heavily on volunteers. Data indicates that most of its residents (92.5%) are white, 2% are Hispanic, 1.8% are multiracial, 1.7% are black, 1.3% are Asian, and 0.6% are American Indian.